Reagila (cariprazine)
- Region
- 🇪🇺 EU
- Active substance
- cariprazine
- Company
- Gedeon Richter
- Status
- Authorised
- Therapeutic area
- Schizophrenia
- CHMP opinion
- Thu 18 May 2017
- EU approval
- Thu 13 Jul 2017
- Application
- EMEA/H/C/002770
- ATC
- N05AX15
- Official record
- www.ema.europa.eu
Indication
Reagila is indicated for the treatment of schizophrenia in adult patients.
Regulatory milestones
No milestones recorded in the last year.
Follow Reagila
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.